Please use this identifier to cite or link to this item: https://doi.org/10.1038/s41408-021-00544-x
Title: A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)
Authors: Chen, Yunxin 
Gopalakrishnan, Sathish Kumar
Ooi, Melissa 
Sultana, Rehena 
Lim, Li Hui
Grigoropoulos, Nicholas 
Ong, Shin Yeu 
Xu, Mingge
Chng, Wee Joo 
Goh, Yeow Tee 
Nagarajan, Chandramouli
Keywords: Science & Technology
Life Sciences & Biomedicine
Oncology
Hematology
MULTIPLE-MYELOMA
LENALIDOMIDE
Issue Date: 3-Sep-2021
Publisher: SPRINGERNATURE
Citation: Chen, Yunxin, Gopalakrishnan, Sathish Kumar, Ooi, Melissa, Sultana, Rehena, Lim, Li Hui, Grigoropoulos, Nicholas, Ong, Shin Yeu, Xu, Mingge, Chng, Wee Joo, Goh, Yeow Tee, Nagarajan, Chandramouli (2021-09-03). A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1). BLOOD CANCER JOURNAL 11 (9). ScholarBank@NUS Repository. https://doi.org/10.1038/s41408-021-00544-x
Source Title: BLOOD CANCER JOURNAL
URI: https://scholarbank.nus.edu.sg/handle/10635/207736
ISSN: 20445385
2044-5385
DOI: 10.1038/s41408-021-00544-x
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with hi.pdf895.33 kBAdobe PDF

OPEN

PublishedView/Download

SCOPUSTM   
Citations

1
checked on May 14, 2022

Page view(s)

52
checked on May 12, 2022

Download(s)

4
checked on May 12, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.